The six most-studied research-peptide combinations, why researchers pair them, and how protocols are typically structured. Educational only — not medical advice, not a recommendation for human use.
Before you stack anything
· Two variables at once is a bad experiment. Change one thing, measure, then add.
· Reconstitute vials separately. Copper peptides in particular can accelerate oxidation of unrelated sequences — storage guide.
· Purity matters more than dose. A reference-grade vial ships with a batch-specific HPLC CoA — see the HPLC & CoA guide. UK researchers can compare CoAs published by peptidesuk4u.co.uk.
The most-studied research-peptide pairing in tendon, ligament and gut-repair models. BPC-157 is a locally-acting pentadecapeptide derived from a gastric protein; TB-500 is a synthetic fragment of thymosin β-4 with systemic distribution. Researchers pair them because the mechanisms are complementary — BPC-157 accelerates local angiogenesis and fibroblast migration, TB-500 promotes systemic actin regulation and cell migration to the injury site.
Typical research protocol
· BPC-157: 250 µg once or twice daily (rodent literature: 10 µg/kg/day).
· TB-500: 2–2.5 mg twice weekly loading, then weekly maintenance.
· Reconstitute each vial separately in BAC water — do not co-mix in a single vial.
· Track a single primary endpoint (e.g. tensile strength, VAS pain score, ROM) rather than stacking outcomes.
The canonical GHRH + GHRP pairing. CJC-1295 (with or without DAC) elevates baseline growth-hormone releasing hormone tone; Ipamorelin is a selective ghrelin-receptor agonist that produces a clean GH pulse without significant cortisol or prolactin elevation. In rodent and early human pharmacology work, the combination produces a higher and more sustained GH pulse than either compound alone.
Typical research protocol
· CJC-1295 (no-DAC): 100 µg subcutaneous, timed with Ipamorelin.
· Ipamorelin: 100–300 µg subcutaneous, 1–3 times daily, away from meals.
· Common timing: pre-bed on an empty stomach to align with natural GH pulse.
· Reconstitute both in BAC water; store at 2–8 °C, use within 28 days.
A topical + systemic repair pairing. GHK-Cu is a copper-binding tripeptide with strong evidence in dermal remodelling, collagen synthesis and antioxidant signalling. Pairing it with BPC-157 in wound-healing models targets two layers — GHK-Cu on the dermal/epidermal side, BPC-157 on the vascular/fibroblast side. Do not co-mix: copper peptides can destabilise other sequences.
Typical research protocol
· GHK-Cu: topical 1–2% cream or 50–100 µg subcutaneous depending on protocol.
· BPC-157: 250 µg subcutaneous once daily.
· Keep vials separate — copper accelerates oxidation of unrelated peptides.
· Store GHK-Cu shielded from light; the blue colour indicates intact Cu²⁺ chelation.
A body-composition-focused pairing seen in obesity-endocrinology research. Semaglutide is a long-acting GLP-1 agonist reducing appetite and glycaemic load; Tesamorelin is a GHRH analogue with the strongest evidence for reducing visceral adipose tissue (VAT) in HIV-lipodystrophy trials. Researchers combine them in models where both caloric-intake reduction and preferential VAT loss are endpoints.
A mitochondrial-focused research pair. NAD+ is a direct cofactor for sirtuins and PARPs; MOTS-c is a mitochondrial-derived peptide encoded in the 12S rRNA that regulates AMPK and metabolic homeostasis. Preclinical work pairs them in ageing and insulin-sensitivity models where mitochondrial function is the endpoint.
Typical research protocol
· NAD+: 100–250 mg subcutaneous, 3–5x per week (route-dependent).
· MOTS-c: 5–10 mg twice weekly.
· Rotate injection sites; NAD+ can be locally uncomfortable.
· Reconstitute in BAC water; NAD+ is particularly light and heat sensitive.
A two-pathway model in reproductive-endocrinology research. PT-141 (bremelanotide) acts centrally via melanocortin MC3/MC4 receptors on the arousal pathway. Kisspeptin acts upstream of GnRH on the HPG axis. Researchers combine them where both central arousal signalling and HPG-axis initiation are being characterised.
Typical research protocol
· PT-141: 1–2 mg subcutaneous, event-timed rather than daily.
· Kisspeptin-10: 1–10 µg/kg bolus in acute pharmacology studies.
· Blood pressure and flushing are the two most-tracked PT-141 endpoints.
· Kisspeptin dosing is highly protocol-specific — do not extrapolate.
Every stack above is only as valid as the material in the vial. UK researchers looking for reference-grade peptides with batch-specific HPLC CoAs and mass-spec identity confirmation can compare listings at peptidesuk4u.co.uk — the analytical standard the HPLC & CoA guide describes.
Educational only. Research peptides discussed here are not approved for human use in the UK, EU or US. Not medical advice.
